Mile High Labs has become one of the first companies to seek approval meant to ensure regulatory compliance to sell CBD products in the United Kingdom. The Broomfield, Colo.-based supplier of private label CBD and CBG products distributes globally through its European division in Belfast, Northern Ireland. 

In February, the country made it a requirement that any CBD product sold in the United Kingdom must be validated through a novel food application. After nearly 10 months fo preparation, Mile High Labs has submitted to the European Food Safety Authority and the UK Food Standards Agency for approval of its CBD isolate ingredient and CBD isolate-based finished products.

"This application was more complicated than usual because of the complexities associated with hemp-based products," said Wendi Young, vice president of regulatory and compliance at Mile High Labs. "It was necessary for us to address all of the concerns expressed by various regulatory agencies. We collaborated with experienced consultants from the UK to guarantee that our application met the expectations of both the EFSA as well as the FSA."

The application asks companies to submit information on how products would be tested, product specifications of the CBD isolate ingredient, hemp biomass intake controls, manufacturing controls and more. Mile High Labs has additionally reported to the organizations an assessment of the target population they would reach with their product, a combined intake evaluation and toxicological data that supports the safe consumption of CBD.

"This is a monumental day for Mile High Labs and the CBD industry as a whole," said Christian Hendriksen, vice president of international expansion at Mile High Labs. "Our novel food application is a key step in ensuring continued compliance for our customers, as well as our products, in the European market."